pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX
MBX Biosciences
MBX Biosciences is a pharma organization headquartered in Carmel, USA. It trades on NYSE under ticker MBX. Primary therapeutic focus areas include Hypoparathyroidism, Postbariatric Hypoglycemia, Renal Impairment, Obesity
Carmel, USA HQ
2019 Founded
74 Employees
Public company Type
MBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carmel, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 7
- Drugs
- 3
- Patents
- 0
MBX 1416 (INN imapextide)
Phase 2 · small molecule · Postbariatric Hypoglycemia
MBX 1416 (INN imapextide) for Postbariatric Hypoglycemia is a Phase 2 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).
Internal code MBX-1P2002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MBX Biosciences
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Postbariatric Hypoglycemia
- Status
- active
- Trials
- 1